ZD-6126

DB11872InvestigationalSmall molecule

ZD6126 has been used in trials studying the treatment of Kidney Neoplasms, Colorectal Neoplasms, Metastases, Neoplasm, and Carcinoma, Renal Cell.

Chemical structure of ZD-6126
Mechanism
Curator reviewed
Formula / weight
C20H24NO8P · 437.385 g/mol (avg)
Code names
ANG-453 · AZD-6126 · ZD 6126 · ZM-445526

Resolves to

Compound
UNIIGBO3S6M9W7CAS219923-05-4ChEMBLCHEMBL257662PubChem9896434
Structure
InChIKeyUGBMEXLBFDAOGL-INIZCTEOSA-NSMILESCOC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=C2C=CC(OP(O)(O)=O)=C3)=C1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of ZD-6126, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In